Serum Institute gets nod for Oxford vaccine Phase 2, 3 trial

The SII has a manufacturing partnership with AstraZeneca, which has got the licence for the vaccine. 

Published: 04th August 2020 05:20 AM  |   Last Updated: 04th August 2020 05:20 AM   |  A+A-

Coronavirus Testing Lab

Representational Image. (Photo | Shekhar Yadav, EPS)

By Express News Service

NEW DELHI: The Drugs Controller General of India has allowed the Serum Institute of India (SII) to conduct Phase-2 and Phase-3 human clinical trials of a potential Covid-19 vaccine, developed by the Oxford University.

The SII has a manufacturing partnership with AstraZeneca, which has got the licence for the vaccine. The experimental vaccine, AZD1222, produced promising immune response in early-stage clinical trials, the Lancet said two weeks ago, raising hopes it would be available for public use by the year-end. 

Sources said the subject expert committee of the Central Drugs Standards Control Organisation gave its nod for the trial on Sunday evening after evaluating it thoroughly. According to the study design, each subject will be administered two doses  of the vaccine four weeks apart (first dose on Day 1 and the second dose on 28th day) following which the safety and immunogenicity will be assessed at predefined intervals. 

SII has to submit safety data of Phase-2, evaluated by the Data Safety Monitoring Board, to the regulator before it can proceed to Phase-3. Currently, Phase 2, 3 clinical trials of the Oxford vaccine are in the UK, while Phase-3 clinical trial has started in Brazil. In South Africa, the vaccine is being assessed in Phase-1 and Phase-2 trials. This vaccine candidate uses a common cold virus, which has been weakened so that it can’t cause any disease in humans, and is genetically modified to code for the spike protein of the SARS-CoV-2 virus. 

Advantage India
India trial is crucial as it will reveal how pre-existing immunity levels will impact response to the Covid-19 vaccine

Stay up to date on all the latest Karnataka news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp